

Summary financial statements in US Dollars

For the year to 31st December 2000

	Business performance			Merger, restructuring and disposal of subsidiaries		Total	
	2000 \$m	1999 \$m	CER %	2000 \$m	1999 \$m	2000 \$m	1999 \$m
Summary profit and loss account							
Sales							
Retained businesses							
• Pharmaceuticals	23,452	22,061	10	–	–	23,452	22,061
• Consumer Healthcare	4,028	4,125	3	–	–	4,028	4,125
	27,480	26,186	9	–	–	27,480	26,186
• Healthcare Services	–	1,024		–	–	–	1,024
Total sales	27,480	27,210		–	–	27,480	27,210
Manufacturing, selling and administration	(16,025)	(15,392)	(9)	(844)	(717)	(16,869)	(16,109)
Research and development	(3,815)	(3,702)	(7)	(24)	–	(3,839)	(3,702)
Healthcare Services	–	(983)		–	(49)	–	(1,032)
Trading profit	7,640	7,133	12	(868)	(766)	6,772	6,367
Other operating income	416	669		–	–	416	669
Income from associates	318	87		(12)	(13)	306	74
Divestments	–	–		2,131	15	2,131	15
Merger transaction costs	–	–		(184)	–	(184)	–
Net interest payable	(277)	(262)		–	–	(277)	(262)
Profit before taxation	8,097	7,627	11	1,067	(764)	9,164	6,863
Taxation	(2,210)	(2,150)		(372)	176	(2,582)	(1,974)
Profit after taxation	5,887	5,477	12	695	(588)	6,582	4,889
Minority interests and preference share dividends	(268)	(257)		–	–	(268)	(257)
Earnings	5,619	5,220	13	695	(588)	6,314	4,632
Earnings per ADS	\$1.85	\$1.71	14			\$2.08	\$1.51
Dividends						3,187	3,248

To illustrate "Business performance", merger items and restructuring costs in 2000 and restructuring costs and disposal of subsidiaries in 1999 have been excluded and an adjusted EPS presented. Business performance growth is at constant exchange rates.

	2000 \$m	1999 \$m
Summary balance sheet		
Fixed assets	15,380	14,960
Current assets	16,790	15,266
Creditors: amounts due within one year	(13,536)	(13,601)
Net current assets	3,254	1,665
Total assets less current liabilities	18,634	16,625
Creditors: amounts due after one year	(2,822)	(3,291)
Provision for liabilities and charges	(2,469)	(2,697)
Net assets	13,343	10,637
Equity shareholders' funds	11,489	8,797
Minority interests	1,854	1,840
Capital employed	13,343	10,637

The financial statements above have been provided in US\$ for the convenience of US shareholders. The profit and loss account has been translated at average exchange rates and the balance sheet at period end exchange rates.